IMPRESS_2: IMPRESS, figure 2

In raredd/kmdata: A Database of Reconstructed Individual Patient Level Data from Oncology Clinical Trials

IMPRESS, figure 2

Description

Kaplan-Meier digitized data from IMPRESS, figure 2 (PMID 26159065). A reported sample size of 265 for a primary endpoint of PFS in lung cancer.

Usage

IMPRESS_2

Format

A data frame of 265 observations and 3 variables:

	time	event time (in months)
	event	PFS event indicator (0: no event, 1: event)
	arm	treatment arms (gefitinib, placebo)

Source

Soria J-C, Wu Y-L, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 2015; 16: 990–8.

Examples

summary(IMPRESS_2)

kmplot(IMPRESS_2)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.